A Phase 1 interventional study of CCH (collagenase clostridium histolyticum) in Edematous Fibrosclerotic Panniculopathy, sponsored by Endo Pharmaceuticals. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-06.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing Microbial Collagenase in Cellulite — none open to participants now, none under way, none of them phase 3. Microbial Collagenase · Cellulite.
Among the 15 studies testing Microbial Collagenase in Cellulite, this one is the 14th largest by enrollment, is one of 5 that started in 2018, is one of 2 in phase 1, and was the 10th registered.
71 studies on the registry are indexed under Cellulite; 3 are open to participants now.
Browse Cellulite studies →None of the 15 studies testing Microbial Collagenase in Cellulite is open now. The open studies under Cellulite, anywhere →
Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1 Cellulite study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 34 across 65 interventional studies indexed under Cellulite.
Median enrollment 150 across the 15 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 2 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
18 studies in Cellulite by Keenova Therapeutics plc: none open now, none under way, none of them phase 3. Of 18 finished, 14 (78%) have results posted.
Among the 18 studies in Cellulite by Keenova Therapeutics plc, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2018, is one of 2 in phase 1, and was the 10th registered.
Keenova Therapeutics plc’s Cellulite studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing Microbial Collagenase in Cellulite, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keenova Therapeutics plc’s 18 in Cellulite:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and Pharmacokinetics (PK) of a single 3.36-mg dose of Collagenase Clostridium Histolyticum (CCH) in 4 quadrants concurrently, in subjects with Edematous fibrosclerotic panniculopathy (EFP).
This study will provide insight to the PK profile and safety of concurrent subcutaneous injections of CCH 0.84 mg/quadrant into 4 quadrants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
No subject will be dosed until all eligibility criteria have been satisfied. In order to be eligible to participate in the study, subjects must meet the following criteria:
Exclusion Criteria:
A subject will be excluded from study participation if she:
Has any of the following systemic conditions:
Has any of the following local conditions in the areas to be treated:
Requires the following concomitant medications before or during participation in the trial:
a. Anticoagulant or antiplatelet medication or has received anticoagulant or antiplatelet medication (except for ≤150 mg aspirin daily) within 7 days before injection of study drug
Has used any of the following for the treatment of EFP on the legs or buttock within the timelines identified below or intends to use any of the following at any time during the course of the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: CCH (collagenase clostridium histolyticum)
A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.
Plasma AUX-I and AUX-II Concentrations
Determine if there is systemic exposure following a subcutaneous single dose of Collagenase clostridium histolyticum (CCH) (3.36 mg) as 12 injections per quadrant in 4 quadrants concurrently (0.84 mg per quadrant) in adult women with Edematous Fibrosclerotic Panniculopathy (EFP). There were no quantifiable levels of plasma AUX-I or AUX-II observed at any collection time point following subcutaneous injection of EN3835. As a result, no pharmacokinetic (PK) parameters were calculated.
Time frame: Day 1 to Day 22
Investigator CR-PCSS Rating
Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit (Baseline) and at End of Study (Day 22). CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.
Time frame: Day 1 to Day 22
Investigator CR-PCSS Change From Baseline
Change from Baseline (Day 22 - Baseline). Baseline Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit. CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.
Time frame: Day 1 to Day 22
Investigator CR-PCSS Responder Analysis at End of Study
Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation at the end of study. CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). A 2-point responder is a participant with a reduction of cellulite severity by at least 2 severity levels from baseline to end of study (i.e., change from baseline CR-PCSS rating of -2, -3, or -4). A 1-point responder is a participant with a reduction of cellulite severity by at least 1 severity level from baseline to end of study (i.e., change from baseline CR-PCSS rating of -1, -2, -3, or -4).
Time frame: Day 22
| Milestone | CCH (Collagenase Clostridium Histolyticum) |
|---|---|
| Started | 12 |
| Completed | 12 |
| Not completed | 0 |
Determine if there is systemic exposure following a subcutaneous single dose of Collagenase clostridium histolyticum (CCH) (3.36 mg) as 12 injections per quadrant in 4 quadrants concurrently (0.84 mg per quadrant) in adult women with Edematous Fibrosclerotic Panniculopathy (EFP). There were no quantifiable levels of plasma AUX-I or AUX-II observed at any collection time point following subcutaneous injection of EN3835. As a result, no pharmacokinetic (PK) parameters were calculated.
| mmol/L | CCH (Collagenase Clostridium Histolyticum) |
|---|---|
| Plasma AUX-I and AUX-II Concentrations | NA ± NA |
Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit (Baseline) and at End of Study (Day 22). CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.
| Participants | Left Buttock | Right Buttock | Left Thigh | Right Thigh |
|---|---|---|---|---|
| Screening (Baseline) — None (0) | 0 | 0 | 0 | 0 |
| Screening (Baseline) — Almost None (1) | 0 | 0 | 0 | 0 |
| Screening (Baseline) — Mild (2) | 6 | 4 | 8 | 8 |
| Screening (Baseline) — Moderate (3) | 4 | 6 | 3 | 3 |
| Screening (Baseline) — Severe (4) | 1 | 1 | 0 | 0 |
| Day 22 (End of Study) — None (0) | 0 | 0 | 0 | 0 |
| Day 22 (End of Study) — Almost None (1) | 1 | 2 | 5 | 5 |
| Day 22 (End of Study) — Mild (2) | 7 | 6 | 5 | 4 |
| Day 22 (End of Study) — Moderate (3) | 3 | 1 | 1 | 2 |
| Day 22 (End of Study) — Severe (4) | 0 | 2 | 0 | 0 |
Change from Baseline (Day 22 - Baseline). Baseline Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit. CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.
| Participants | Left Buttock | Right Buttock | Left Thigh | Right Thigh |
|---|---|---|---|---|
| -4 | 0 | 0 | 0 | 0 |
| -3 | 0 | 0 | 0 | 0 |
| -2 | 0 | 1 | 1 | 0 |
| -1 | 5 | 4 | 5 | 7 |
| 0 | 5 | 5 | 5 | 3 |
| +1 | 1 | 1 | 0 | 1 |
| +2 | 0 | 0 | 0 | 0 |
Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation at the end of study. CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). A 2-point responder is a participant with a reduction of cellulite severity by at least 2 severity levels from baseline to end of study (i.e., change from baseline CR-PCSS rating of -2, -3, or -4). A 1-point responder is a participant with a reduction of cellulite severity by at least 1 severity level from baseline to end of study (i.e., change from baseline CR-PCSS rating of -1, -2, -3, or -4).
| Participants | Left Buttock | Right Buttock | Left Thigh | Right Thigh |
|---|---|---|---|---|
| 2-point Responder — Yes | 0 | 1 | 1 | 0 |
| 2-point Responder — No | 11 | 10 | 10 | 11 |
| 1-point Responder — Yes | 5 | 5 | 6 | 7 |
| 1-point Responder — No | 6 | 6 | 5 | 4 |
Collected over All (serious and nonserious) AEs, from Day 1 up to Day 22. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CCH (Collagenase Clostridium Histolyticum) | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| Event | CCH (Collagenase Clostridium Histolyticum) |
|---|---|
| Injection site bruisingGeneral disorders | 12/12 |
| Injection site painGeneral disorders | 12/12 |
| Injection site oedemaGeneral disorders | 4/12 |
| Injection site swellingGeneral disorders | 2/12 |
| HeadacheNervous system disorders | 2/12 |
| ChillsGeneral disorders | 1/12 |
| Injection site erythemaGeneral disorders | 1/12 |
| Injection site noduleGeneral disorders | 1/12 |
| Injection site pruritusGeneral disorders | 1/12 |
| Injection site warmthGeneral disorders | 1/12 |
| Age, Continuous(years) | CCH (Collagenase Clostridium Histolyticum) |
|---|---|
| Mean | 49.3 ± 10.19 |
| Sex: Female, Male(Participants) | CCH (Collagenase Clostridium Histolyticum) |
|---|---|
| Female | 12 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | CCH (Collagenase Clostridium Histolyticum) |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | CCH (Collagenase Clostridium Histolyticum) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 6 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Body Mass Index (BMI)((kg/m^2)) | CCH (Collagenase Clostridium Histolyticum) |
|---|---|
| Mean | 29.94 ± 3.574 |
| Skin Category (Fitzpatrick Scale)(Participants) | CCH (Collagenase Clostridium Histolyticum) |
|---|---|
| I (Pale White) | 0 |
| II (Fair) | 1 |
| III (Darker White) | 4 |
| IV (Light Brown) | 3 |
| V (Brown) | 1 |
| VI (Dark Brown or Black) | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Sep 2018 to primary completion in Nov 2018, 1 month.
Results were first posted in Oct 2020, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase